Pharmacogenomics in pediatric rheumatology

Current Opinion in Rheumatology

Volumn 24, Issue 5, 2012, Pages 541-547

  Becker, Mara L ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Individualized therapeutics; pediatric rheumatology; pharmacogenomics

Indexed keywords

ABC TRANSPORTER; ADENOSINE; ADENOSINE A2 RECEPTOR; ANTIMETABOLITE; AZATHIOPRINE; CYTOCHROME P450; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA GLUTAMYL HYDROLASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIPROLIFERATIVE ACTIVITY; DRUG RESPONSE; DRUG TRANSFORMATION; EPISTASIS; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PEDIATRICS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRIMIDINE SYNTHESIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIMETABOLITES; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; BIOLOGICAL AGENTS; CHILD; HUMANS; INDIVIDUALIZED MEDICINE; METHOTREXATE; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; PHARMACOGENETICS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 84864883035     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283556d13     Document Type: Review

References (60)

1. Deal CL, Hooker R, Harrington T, et al. The United States rheumatology workforce: supply and demand 2005-2025. Arthritis Rheum 2007; 56:722-729.
2. Wilson JT. An update on the therapeutic orphan. Pediatrics 1999; 104:585-590.
3. Kauffman RE. Drug safety, testing, and availability for children. Child Legal Rights J 1998; 18:28-34.
4. Ward RM, Bates BA, Benitz WE, et al. Committee on Drugs. American Academy of Pediatrics. Uses of Drugs Not Described in the Package Insert (Off-Label Uses). Pediatrics 2002; 110:181-183.
5. Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 2007; 161:282-290.
6. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349:1157-1167.
7. Mulla H. Understanding developmental pharmacodynamics: importance for drug development and clinical practice. Paediatr Drugs 2010; 12:223-233.
8. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008; 118:250-267.
9. Leeder JS, Kearns GL, Spielberg SP, et al. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 2010; 50:1377-1387.
10. Becker M, Leeder J. Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate. Human Genomics and Proteomics, 2010; 1-9. doi: 10.4061/2010/257120.
11. Becker ML, Leeder JS. Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics 2010; 11:1591-1602.
12. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50:2191-2201.
13. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92:2675-2682.
14. Allegra CJ, Chabner BA, Drake JC, et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985; 260:9720-9726.
15. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003; 66:403-456.
16. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985; 76:907-912.
17. Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50:2766-2774.
18. Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics 2011; 12:1449-1463.
19. Ranganathan P. Pharmacogenomics in rheumatoid arthritis. Methods Mol Biol 2008; 448:413-435.
20. Dervieux T, Wessels JA, van der Straaten T, et al. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics 2009; 19:935-944.
21. Dervieux T, Wessels JA, Kremer JM, et al. Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet Genomics 2012; 22:1-9.
22. Becker ML, Gaedigk R, van Haandel L, et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011; 63:276-285.
23. Becker ML, vanHaandel L, Gaedigk R, et al. Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variability. Pharmacogenet Genomics 2012; 4:236-246.
24. Hinks A, Moncrieffe H, Martin P, et al. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis 2011; 70:1395-1400.
25. Moncrieffe H, Hinks A, Ursu S, et al. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. Pharmacogenet Genomics 2010; 20:665-676.
26. Kalnitsky A, Rosenblatt D, Zlotkin S. Differences in liver folate enzyme patterns in premature and full term infants. Pediatr Res 1982; 16:628-631.
27. Thompson HR, Jones GM, Narkewicz MR. Ontogeny of hepatic enzymes involved in serine-and folate-dependent one-carbon metabolism in rabbits. Am J Physiol Gastrointest Liver Physiol 2001; 280:G873-G878.
28. Snell K. Liver enzymes of serine metabolism during neonatal development of the rat. Biochem J 1980; 190:451-455.
29. Narkewicz MR, Moores RR Jr, Battaglia FC, et al. Ontogeny of serine hydroxymethyltransferase isoenzymes in fetal sheep liver, kidney, and placenta. Mol Genet Metab 1999; 68:473-480.
30. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46:149-154.
31. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001-2008.
32. Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 85:164-172.
33. Becker ML. Optimization of pediatric rheumatology therapeutics. Clin Pharmacol Ther 2012; 91:597-606.
34. Ganiere-Monteil C, Medard Y, Lejus C, et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol 2004; 60:89-96.
35. Park-Hah JO, Klemetsdal B, Lysaa R, et al. Thiopurine methyltransferase activity in a Korean population sample of children. Clin Pharmacol Ther 1996; 60:68-74.
36. Cassidy JT, Petty RE, Lindsley CB, Laxer RM, editors. Textbook of Pediatric Rheumatology. 5th ed. 2005, Saunders.
37. Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 2010; 11:369-390.
38. Baldelli S, Merlini S, Perico N, et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 2007; 8:1127-1141.
39. Levesque E, Delage R, Benoit-Biancamano MO, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007; 81:392-400.
40. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86:1043-1051.
41. Gaston RS, Kaplan B, Shah T, et al. Fixed-or controlled-dose mycophenolate mofetil with standard-or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 2009; 9:1607-1619.
42. Zhao W, Fakhoury M, Deschenes G, et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients. J Clin Pharmacol 2010; 50:1280-1291.
43. Sagcal-Gironella AC, Fukuda T, Wiers K, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum 2011; 40:307-313.
44. Strassburg CP, Strassburg A, Kneip S, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002; 50:259-265.
45. Allegaert K, Vanhaesebrouck S, Verbesselt R, van den Anker JN. In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age. Ther Drug Monit 2009; 31:411-415.
46. Zhao W, Fakhoury M, Jacqz-Aigrain E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther Drug Monit 2010; 32:688-699.
47. Donnithorne KJ, Cron RQ, Beukelman T. Attainment of inactive disease status following initiation of TNF-alpha inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. J Rheumatol 2011; 38:2675-2681.
48. Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011; 306:2340-2347.
49. Prajapati R, Plant D, Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics 2011; 12:1571-1585.
50. O'Rielly DD, Roslin NM, Beyene J, et al. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J 2009; 9:161-167.
51. Pavy S, Toonen EJ, Miceli-Richard C, et al. Tumour necrosis factor alpha-308G-→A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2010; 69:1022-1028.
52. Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008; 17:3532-3538.
53. Coulthard LR, Taylor JC, Eyre S, et al. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis 2011; 70:98-103.
54. Cui J, Saevarsdottir S, Thomson B, et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to antitumor necrosis factor alpha therapy. Arthritis Rheum 2010; 62:1849-1861.
55. Plant D, Prajapati R, Hyrich KL, et al. Replication of association of the PTPRC gene with response to antitumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 2012; 64:665-670.
56. Liu C, Batliwalla F, Li W, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008; 14:575-581.
57. Suarez-Gestal M, Perez-Pampin E, Calaza M, et al. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study. Arthritis Res Ther 2010; 12:R72.
58. Plant D, Bowes J, Potter C, et al. Genome-wide association study of genetic predictors of antitumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum 2011; 63:645-653.
59. Zhang X, Morcos PN, De Benedetti F, et al. Pharmacokinetics (PK) and Pharmacodynamics (PD) of tocilizumab in systemic juvenile idiopathic arthritis. Clin Pharmacol Ther 2011; 89(Supplement 1): S36.
60. Goldman JL, Davis HM, Zhou H, Kearns GL, Association of infliximab clearance and resting energy expenditure in children. Clin Pharmacol Ther, 2010; 89(supplement 1): S36.